Today I am looking at four FTSE superstars poised to shell out huge rewards.
While it is true that AstraZeneca (LSE: AZN) faces further patent pressures across its pills portfolio, I believe that the companys supercharged R&D operations combined with galloping healthcare demand in developing regions makes it a terrific long-term selection for those seeking formidable dividend prospects.
And in the meantime, AstraZenecas brilliant cash-generative qualities are anticipated to keep payouts bubbling along at brilliant levels. The London company is predicted to buck three consecutive earnings losses with a marginal 1% uptick in 2015, a result good enough to push the dividend to 285 US cents per share from 280 cents, or so say the Citys number crunchers. And with the payout predicted to be held at this level next year, the pharma giant sports a mammoth 4.4% yield through to end-2016.
Supported by expectations of splendid, double-digit earnings expansion this year and next, construction contractor Kier (LSE: KIE) is predicted to keep its progressive dividend policy firmly in business. The company has lifted the payout at a chunky compound annual dividend growth rate of 5.6% since 2010, and with a strong British economy likely to boost the number of contracts coming through the firms doors, I reckon Kier is in great shape to enjoy solid revenues growth looking well ahead.
The building and engineering play is reckoned to lift the full-year dividend to 61.1p per share for the year concluding June 2015, up from 57.53p in the previous year and producing a hefty yield of 4.2%. And this readout rises to a resplendent 4.5% amid projections of a tasty 66.5p reward.
Like Kier, pub operator Marstons (LSE: MARS) is expected to enjoy chunky dividend growth in the years ahead, finally putting to bed the earnings travails of recent times. With the companys restructuring drive boosting the number of new outlets and underperforming ones, and moves such as the acquisition of Thwaites beer operations boosting its exposure to the booming premium ale sector, I reckon the stage is set for both profits and payouts to keep marching on.
This view is shared by the calculator bashers, and Marstons is predicted to raise a payment of 6.7p per share for the year concluding October 2014 to 7p for the current period, creating a juicy yield of 4.3%. And predictions of a further hike in 2016, to 7.4p, pushes the yield to an even-tastier 4.5%.
De La Rue
Money and passport printers De La Rue (LSE: DLAR) has been in the wars in recent times as challenging trading conditions have smashed the bottom line. Pre-tax profit dipped by more than a third in the year ending March 2015 to 38.9m, the Basingstoke business crimped by lower contract prices despite higher volumes, not to mention the issue of escalating paper costs.
Consequently De La Rue cut the full-year payout to 25p per share in 2015 from 42.3p in the years before. Still, the City expects the currency experts to keep the payment locked around these levels in both 2016 and 2017. Such projections create a barnstorming yield of 4.7%, and although investors should bear in mind the enduring market pressures facing De La Rue, the results of the 200-year-old banknote makers new strategic plan which includes boosting investment in higher growth and more profitable markets could make the business a top-drawer turnaround play.
So if you are looking for more dividend darlings like those mentioned, I strongly recommend you check out this totally exclusive report that picks out a wide array of blue-chip wonders poised to deliver splendid dividend flows.
Our “5 Dividend Winners To Retire On” wealth report highlights a selection of incredible stocks with an excellent record of providing juicy shareholder returns. Among our picks are top retail, pharmaceutical and utilities plays that we are convinced should continue to provide red-hot dividends. Click here to download the report — it’s 100% free and comes with no further obligation.